Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Market Closed 03-27 16:00:00 EDT

26.52

-0.83

-3.03%

盘后26.00

-0.52-1.96%

19:51 EDT

High27.51	Low26.47	Vol3.01M
Open27.26	D1 Closing27.35	Amplitude3.80%
Mkt Cap18.98B	Tradable Cap12.38B	Total Shares715.70M
T/O80.67M	T/O Rate0.64%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":26.52,"timestamp":1774641600000,"preClose":27.35,"halted":0,"volume":3011878,"hourTrading":{"tag":"盘后","latestPrice":26,"preClose":26.52,"latestTime":"19:51 EDT","volume":60579,"amount":1603294.66,"timestamp":1774655502579,"change":-0.52,"changeRate":-0.019608,"amplitude":0.038462},"delay":0,"changeRate":-0.03034734917733096,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"Market Closed","change":-0.83,"latestTime":"03-27 16:00:00 EDT","open":27.26,"high":27.51,"low":26.47,"amount":80670004.81749,"amplitude":0.038026,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":27.35,"preHourTrading":{"tag":"盘前","latestPrice":27.4,"preClose":27.35,"latestTime":"08:21 EDT","volume":282,"amount":7726.81974,"timestamp":1774614076068,"change":0.05,"changeRate":0.001828,"amplitude":0.000366},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":26.52,"latestTime":"19:51 EDT","volume":60579,"amount":1603294.66,"timestamp":1774655502579,"change":-0.52,"changeRate":-0.019608,"amplitude":0.038462},"volumeRatio":0.383205,"impliedVol":0.3238,"impliedVolPercentile":0.4223},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2623338960","title":"BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338960","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623338960?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:26","pubTimestamp":1774726019,"startTime":"0","endTime":"0","summary":"BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In DermatomyositisMarch 28 (Reuters) - Roivant Sciences Ltd ROIV.O:NEW ENGLAND JOURNAL OF MEDICINE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nTUA7Q9L0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2623388803","title":"Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2623388803","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623388803?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724430,"startTime":"0","endTime":"0","summary":"Roivant reported New England Journal of Medicine publication of Phase 3 VALOR results for brepocitinib in adults with dermatomyositis.Trial met primary endpoint, with brepocitinib 30 mg once daily delivering 15.3-point greater improvement in mean Total Improvement Score at Week 52 versus placebo .Data showed clinically meaningful steroid-sparing effect, with nearly twice as many patients reducing background corticosteroids in brepocitinib 30 mg group versus placebo.Safety profile showed higher serious infection rate with brepocitinib 30 mg versus placebo, while discontinuations were more frequent on placebo.Additional VALOR analyses were already presented at 2026 American Academy of Dermatology meeting; FDA granted Priority Review with PDUFA target action date in Q3 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL3JjHDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","SG9999014039.USD","ROIV","IE00BN0W2W23.USD","NDAQ","SG9999014013.SGD","BK4112","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4585","BK4588","BK4007","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2623881338","title":"Roivant Sciences Ltd - FDA Grants Priority Review to Brepocitinib Nda With Pdufa Date in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623881338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623881338?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nTUA7Q9L0N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2623800023","title":"New England Journal of Medicine Publishes Positive Phase 3 Valor Trial Results of Brepocitinib in Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2623800023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623800023?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nTUA7Q9L0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2622914877","title":"Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622914877","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622914877?lang=en_us&edition=fundamental","pubTime":"2026-03-28 03:04","pubTimestamp":1774638299,"startTime":"0","endTime":"0","summary":"In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology.\nThese analyst actions suggest the settlement is shifting attention away from legal risk and toward Roivant’s upcoming clinical trial milestones in pulmonary hypertension and non-infectious uveitis.\nWe’ll now examine how the Moderna settlement, seen as clearing a legal overhang, may influence Roivant’s existing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2621757705","title":"Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757705","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621757705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:44","pubTimestamp":1774269897,"startTime":"0","endTime":"0","summary":"Roivant filed an amended Form 8-K to correct its earlier report by filing the Settlement Agreement as an exhibit.The amendment relates to a March 3, 2026 settlement between Genevant and Arbutus and Moderna that resolves patent infringement litigation over lipid nanoparticle delivery technology used in Moderna vaccines.Roivant said no other changes were made to the original Form 8-K disclosures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLbCGm6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","ROIV","BK4501","MRNY","BK4534","BK4551","BK4585","BK4532","MRNX","BK4568","BK4533","BK4007","BK4588","MRNA","BK4139"],"gpt_icon":0},{"id":"2620806739","title":"Bernstein bullish on Roivant Sciences, initiates with an Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2620806739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620806739?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:50","pubTimestamp":1774011045,"startTime":"0","endTime":"0","summary":"As previously reported, Bernstein initiated coverage of Roivant Sciences (ROIV) with an Outperform rating and $35 price target The firm sees upside...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bernstein-bullish-on-roivant-sciences-initiates-with-an-outperform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bernstein-bullish-on-roivant-sciences-initiates-with-an-outperform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2620782284","title":"Roivant Sciences Ltd : Bernstein Initiates Coverage With Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782284?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:17","pubTimestamp":1774001832,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2620725052","title":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of USD 5.65 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620725052","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620725052?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:37","pubTimestamp":1773959842,"startTime":"0","endTime":"0","summary":"Eric Venker, President and Immunovant CEO, reported a change in beneficial ownership of Roivant common shares dated 03/17/2026.He acquired 200,000 common shares at USD 3.85 per share through an option exercise.Venker sold 200,000 common shares at USD 28.24 per share.Directly held common shares after the transactions totaled 1,647,546.Stock options beneficially owned after the transaction totaled 4,844,834.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4w0c0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","IMVT","BK4585","BK4007","BK4588","BK4139"],"gpt_icon":0},{"id":"2620293480","title":"Roivant Sciences director Melissa B. Epperly disposes of USD 1.2 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620293480","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620293480?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:24","pubTimestamp":1773872645,"startTime":"0","endTime":"0","summary":"Melissa Epperly, a director at Roivant Sciences, reported selling 41,861 common shares on March 16, 2026. The shares were sold at a weighted average price of USD 28.68 per share. Following the transaction, Epperly beneficially owned 15,804 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbcGXyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences director Melissa B. Epperly disposes of USD 1.2 million in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2618611303","title":"Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618611303?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:45","pubTimestamp":1773027916,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Roivant Sciences yesterday and set a price target of $34.00. According to TipRanks,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2616655953","title":"Moderna litigation outcome ‘favorable,’ but leaves some risk, says BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2616655953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616655953?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:37","pubTimestamp":1772635026,"startTime":"0","endTime":"0","summary":"BofA contends that Moderna’s (MRNA) settlement with Arbutus (ABUS) and Genevant (ROIV) takes “a meaningful chunk of the litigation overhang off the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-litigation-outcome-favorable-but-leaves-some-risk-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-litigation-outcome-favorable-but-leaves-some-risk-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4568","MRNA","BK4534","BK4139","BK4551","BK4588","BK4548","MRNX","BK4532","ABUS","BK4533","BK4585","BK4501","MRNY","BK4007"],"gpt_icon":0},{"id":"1118198243","title":"Moderna to Pay $2.25 Billion Settlement to Resolve LNP Patent Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=1118198243","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118198243?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:41","pubTimestamp":1772631686,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has agreed to pay up to $2.25 billion to Roivant Sciences Ltd. (ROIV) to settle intellectual property claims related to the lipid nanoparticle technology used in its COVID-19 vaccine. The agreement prevents a jury trial that was scheduled to begin next week.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SINA","BK4139","ROIV"],"gpt_icon":0},{"id":"2616558924","title":"Guggenheim Sticks to Their Buy Rating for Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558924?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:52","pubTimestamp":1772628754,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja maintained a Buy rating on Roivant Sciences yesterday and set a price target of $30.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV"],"gpt_icon":0},{"id":"2616532801","title":"Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532801","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532801?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:53","pubTimestamp":1772625180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 06:53 ET (11:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2616531089","title":"BUZZ-Street View: Wall Street views Moderna's legal settlement as clearing a major overhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616531089?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:18","pubTimestamp":1772623108,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Wall Street views Moderna's legal settlement as clearing a major overhang** Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4N3ZS0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4568","MRNA","BK4534","BK4139","BK4551","BK4588","BK4548","MRNX","BK4532","ABUS","BK4533","BK4585","BK4501","MRNY","BK4007"],"gpt_icon":0},{"id":"2616534318","title":"Roivant Sciences price target raised to $34 from $33 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616534318","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616534318?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:15","pubTimestamp":1772622910,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $33 and keeps a Buy rating on the shares. The firm added the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-33-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-33-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2616374941","title":"Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374941","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374941?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:52","pubTimestamp":1772578370,"startTime":"0","endTime":"0","summary":"Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZR21P:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MRNX","BK4588","BK4548","BK4551","BK4568","MRNY","BK4007","BK4534","MRNA","BK4585","BK4501","ABUS","ROIV","BK4139","BK4533"],"gpt_icon":0},{"id":"2616775113","title":"Roivant Sciences Raises Buyback Program to $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2616775113","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616775113?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:11","pubTimestamp":1772575860,"startTime":"0","endTime":"0","summary":"Roivant Sciences has added $500 million to its current share repurchase program.The pharmaceutical company said Tuesday that its board of directors approved a share repurchase program of up to $1 billion, including a previously announced $500 million authorization.The repurchase program will be funded with available cash and cash equivalents on hand and doesn't have an expiration date, the company said.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roivant Sciences Raises Buyback Program to $1 Billion","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2616374698","title":"BRIEF-Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374698","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374698?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:20","pubTimestamp":1772572836,"startTime":"0","endTime":"0","summary":"BRIEF-Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaMarch 3 (Reuters) - Arbutus Biopharma Corp ABUS.O:GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA7RZBMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ABUS","ROIV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0426},{"period":"1month","weight":-0.0747},{"period":"3month","weight":0.193},{"period":"6month","weight":0.7482},{"period":"1year","weight":1.5305},{"period":"ytd","weight":0.2221}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.094396},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}